{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:30:24Z","timestamp":1740130224099,"version":"3.37.3"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the impact of incorporating treatment guidance into reporting of urate test results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Urate targets for clinically confirmed gout were added to urate results above 0.36\u2009mmol\/l requested after September 2014 within NHS Lothian. Scotland-wide data on urate-lowering therapy prescriptions and hospital admissions with gout were analysed between 2009 and 2020. Local data on urate tests were analysed between 2014 and 2015.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Admissions with a primary diagnosis of gout in Lothian reduced modestly following the intervention from 111\/year in 2010\u20132014 to 104\/year in 2015\u20132019, a non-significant difference (P\u2009=\u20090.32). In contrast there was a significant increase in admissions to remaining NHS Scotland health boards (556\/year vs 606\/year, P\u2009&amp;lt;\u20090.01). For a secondary diagnosis of gout the number of admissions in NHS Lothian reduced significantly (58\/year vs 39\/year, P\u2009&amp;lt;\u20090.01) contrasting with a significant increase in remaining Scottish health boards (220\/year vs 290\/year, P\u2009&amp;lt;\u20090.01). The relative rate of admissions to NHS Lothian compared with remaining Scottish boards using a 2009 baseline were significantly reduced for both primary diagnosis of gout (1.06 vs 1.25, P\u2009&amp;lt;\u20090.001) and secondary diagnoses of gout (0.64 compared with 1.4, P\u2009&amp;lt;\u20090.001) after the intervention; however, there was no difference before the intervention. A relative increase in the prescription rates of allopurinol 300\u2009mg tablets and febuxostat 120\u2009mg tablets may have contributed to the improved outcomes seen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Incorporation of clinical guideline advice into routine reporting of urate results was associated with reduced rates of admission with gout in NHS Lothian, in comparison with other Scottish health boards.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab689","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T11:11:45Z","timestamp":1631531505000},"page":"1885-1891","source":"Crossref","is-referenced-by-count":0,"title":["Incorporating gout guideline advice into urate reports is associated with reduced hospital admissions: results of an observational study"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3029-7098","authenticated-orcid":false,"given":"Philip L","family":"Riches","sequence":"first","affiliation":[{"name":"Rheumatic Diseases Unit, Western General Hospital, NHS Lothian, Edinburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Downie","sequence":"additional","affiliation":[{"name":"Public Health Scotland, Meridian Court, Glasgow"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Thomson","sequence":"additional","affiliation":[{"name":"Laboratory Services, NHS Lothian, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"2022050522152858200_keab689-B1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022050522152858200_keab689-B2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/rheumatology\/kes253","article-title":"Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999\u20132009","volume":"52","author":"Robinson","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2022050522152858200_keab689-B3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022050522152858200_keab689-B4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"2022050522152858200_keab689-B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","article-title":"The effect of serum urate on gout flares and their associated costs: an administrative claims analysis","volume":"15","author":"Halpern","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"2022050522152858200_keab689-B6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/rheumatology\/keq346","article-title":"Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout","volume":"50","author":"Khanna","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2022050522152858200_keab689-B7","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2022050522152858200_keab689-B8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022050522152858200_keab689-B9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.semarthrit.2014.01.004","article-title":"Up-titration of allopurinol in patients with gout","volume":"44","author":"Jennings","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2022050522152858200_keab689-B10","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.2007.076232","article-title":"Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005","volume":"67","author":"Annemans","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2022050522152858200_keab689-B11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","article-title":"Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD)","volume":"44","author":"Mikuls","year":"2005","journal-title":"Rheumatology (Oxford)"},{"year":"2012","key":"2022050522152858200_keab689-B12"},{"key":"2022050522152858200_keab689-B13","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1365-2753.2008.01014.x","article-title":"The effectiveness of clinical guideline implementation strategies \u2013 a synthesis of systematic review findings","volume":"14","author":"Prior","year":"2008","journal-title":"J Eval Clin Pract"},{"key":"2022050522152858200_keab689-B14","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/rheumatology\/kex530","article-title":"Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies","volume":"57","author":"Rai","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2022050522152858200_keab689-B15","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab689\/40495112\/keab689.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/1885\/43562169\/keab689.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/1885\/43562169\/keab689.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T22:22:41Z","timestamp":1651789361000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/5\/1885\/6370969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,9,16]]},"published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab689","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,9,16]]}}}